Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Regenerative Medicine Foundation to hold a summit » 04:55
01/22/20
01/22
04:55
01/22/20
04:55
ABC

AmerisourceBergen

$91.24 /

+0.18 (+0.20%)

, ATHX

Athersys

$1.28 /

+0.01 (+0.79%)

, BLUE

Bluebird Bio

$95.90 /

-2.17 (-2.21%)

, CLBS

Caladrius

$2.90 /

-0.29 (-9.09%)

, CYRX

Cryoport

$19.41 /

+0.13 (+0.67%)

, GLW

Corning

$29.72 /

-0.35 (-1.16%)

, HEMA

HemaCare

$0.00 /

+ (+0.00%)

, IOVA

Iovance Biotherapeutics

$23.65 /

-0.22 (-0.92%)

, IQV

Iqvia

$160.82 /

-0.68 (-0.42%)

, LZAGY

Lonza

$0.00 /

+ (+0.00%)

, MBIO

Mustang Bio

$4.24 /

-0.09 (-2.08%)

, MCK

McKesson

$155.27 /

-1.05 (-0.67%)

, NVO

Novo Nordisk

$61.15 /

-0.16 (-0.26%)

, NWBO

Northwest Biotherapeutics

$0.00 /

+ (+0.00%)

, SYNH

Syneos Health

$63.87 /

-0.16 (-0.25%)

, TECH

Bio-Techne

$221.53 /

+1.08 (+0.49%)

, THMO

ThermoGenesis

$4.76 /

+0.06 (+1.28%)

, TMO

Thermo Fisher

$337.38 /

-1.77 (-0.52%)

15th Annual World Stem…

15th Annual World Stem Cell Summit will be held in Miami on January 21-24.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Yesterday
Conference/Events
Regenerative Medicine Foundation to hold a summit » 07:57
01/21/20
01/21
07:57
01/21/20
07:57
ABC

AmerisourceBergen

$91.06 /

-0.42 (-0.46%)

, ATHX

Athersys

$1.27 /

-0.015 (-1.17%)

, BLUE

Bluebird Bio

$98.07 /

+0.41 (+0.42%)

, CLBS

Caladrius

$3.19 /

-0.075 (-2.30%)

, CYRX

Cryoport

$19.28 /

+0.26 (+1.37%)

, GLW

Corning

$30.07 /

+0.05 (+0.17%)

, HEMA

HemaCare

$0.00 /

+ (+0.00%)

, IOVA

Iovance Biotherapeutics

$23.87 /

+0.13 (+0.55%)

, IQV

Iqvia

$161.50 /

+0.51 (+0.32%)

, LZAGY

Lonza

$0.00 /

+ (+0.00%)

, MBIO

Mustang Bio

$4.33 /

-0.19 (-4.20%)

, MCK

McKesson

$156.32 /

+0.07 (+0.04%)

, NVO

Novo Nordisk

$61.31 /

+0.02 (+0.03%)

, NWBO

Northwest Biotherapeutics

$0.00 /

+ (+0.00%)

, SYNH

Syneos Health

$64.03 /

+0.17 (+0.27%)

, TECH

Bio-Techne

$220.45 /

+1.18 (+0.54%)

, THMO

ThermoGenesis

$4.70 /

-0.15 (-3.09%)

, TMO

Thermo Fisher

$339.15 /

+2.34 (+0.69%)

15th Annual World Stem…

15th Annual World Stem Cell Summit will be held in Miami on January 21-24.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Hot Stocks
Bluebird Bio announces launch of ZYNTEGLO in Germany » 05:50
01/13/20
01/13
05:50
01/13/20
05:50
BLUE

Bluebird Bio

$90.55 /

-0.45 (-0.49%)

bluebird bio announced…

bluebird bio announced the launch in Germany of ZYNTEGLO, a one-time gene therapy for patients 12 years and older with transfusion-dependent beta-thalassemia, or TDT, who do not have a beta0/beta0 genotype, for whom hematopoietic stem cell, or HSC, transplantation is appropriate but a human leukocyte antigen, or HLA,-matched related HSC donor is not available. This is the first time ZYNTEGLO is commercially available. TDT is a severe genetic disease caused by mutations in the beta-globin gene that result in significantly reduced or absent adult hemoglobin, or HbA. In order to survive, people with TDT maintain hemoglobin (Hb) levels through lifelong chronic blood transfusions. These transfusions carry the risk of progressive multi-organ damage due to unavoidable iron overload. ZYNTEGLO is a one-time gene therapy that addresses the underlying genetic cause of TDT and offers patients the potential to become transfusion independent, which, once achieved, is expected to be lifelong. Due to the highly technical and specialized nature of administering gene therapy in rare diseases, bluebird bio is working with institutions that have expertise in stem cell transplant as well as in treating patients with TDT to create qualified treatment centers that will administer ZYNTEGLO. bluebird bio has established a collaboration with University Hospital of Heidelberg as the first qualified treatment center in Germany. In addition, bluebird has entered into value-based payment agreements with multiple statutory health insurances in Germany to help ensure patients and their healthcare providers have access to ZYNTEGLO and that payers only pay if the therapy delivers on its promise. bluebird's proposed innovative model is limited to five payments made in equal installments. An initial payment is made at the time of infusion. The four additional annual payments are only made if no transfusions for TDT are required for the patient.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Goldman Sachs to hold a conference » 08:03
01/09/20
01/09
08:03
01/09/20
08:03
ABAC

Ticker changed to BIQI

$0.00 /

+ (+0.00%)

, AMGN

Amgen

$238.24 /

+0.22 (+0.09%)

, BLUE

Bluebird Bio

$91.70 /

+1.645 (+1.83%)

, BMRN

BioMarin

$84.73 /

+0.515 (+0.61%)

, BMY

Bristol-Myers

$63.88 /

-0.06 (-0.09%)

, CRSP

Crispr Therapeutics

$62.53 /

+2.11 (+3.49%)

, GS

Goldman Sachs

$237.77 /

+2.29 (+0.97%)

, HUM

Humana

$374.77 /

+8.14 (+2.22%)

, TFX

Teleflex

$379.59 /

+0.26 (+0.07%)

12th Annual Healthcare…

12th Annual Healthcare CEOs Unscripted Conference will be held in New York on January 9.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Recommendations
BioMarin, Vertex among JPMorgan's top Biotech picks for 2020 » 07:48
12/18/19
12/18
07:48
12/18/19
07:48
BMRN

BioMarin

$83.38 /

-0.16 (-0.19%)

, VRTX

Vertex

$217.62 /

-1.71 (-0.78%)

, APLS

Apellis

$29.49 /

+0.86 (+3.00%)

, MYOK

MyoKardia

$66.65 /

-0.18 (-0.27%)

, ASND

Ascendis Pharma

$124.51 /

+6.5 (+5.51%)

, KPTI

Karyopharm

$17.05 /

+0.05 (+0.29%)

, ACAD

Acadia

$46.09 /

+0.05 (+0.11%)

, GILD

Gilead

$66.19 /

+0.07 (+0.11%)

, UTHR

United Therapeutics

$89.43 /

-1.43 (-1.57%)

, BLUE

Bluebird Bio

$95.10 /

+3.47 (+3.79%)

, SAGE

Sage Therapeutics

$68.98 /

-1.04 (-1.49%)

After a…

After a "volatile" 2019, the biotech group is heading into 2020 with positive momentum, analysts at JPMorgan tells investors in a research note. Receding concerns about the potential for healthcare reform, coupled with an uptick in acquisitions, drove a Q4 rally, according to the analysts. They see "multiple signs for optimism" regarding the sustainability of the rally into 2020. JPMorgan's top picks in Biotech are BioMarin (BMRN), Vertex (VRTX), Apellis (APLS), MyoKardia (MYOK), Ascendis Pharma (ASND) and Karyopharm (KPTI). Other names to consider, says the analysts, are Acadia (ACAD), Gilead (GILD), United Therapeutics (UTHR), Bluebird Bio (BLUE) and Sage Therapeutics (SAGE).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Fly Intel: Top five analyst upgrades » 10:19
12/13/19
12/13
10:19
12/13/19
10:19
SNAP

Snap

$14.86 /

+0.41 (+2.84%)

, CIEN

Ciena

$43.68 /

+0.94 (+2.20%)

, BMY

Bristol-Myers

$64.65 /

+0.685 (+1.07%)

, BLUE

Bluebird Bio

$86.90 /

+2.9 (+3.45%)

, NUVA

NuVasive

$76.00 /

+2.25 (+3.05%)

Catch up on today's…

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) upgraded to Outperform from Market Perform at JMP Securities with analyst Ronald Josey saying he is "incrementally confident" in Snap's ability to grow its user base, increase engagement, and improve overall monetization as the service attracts more advertisers and share of advertising budgets. 2. Ciena (CIEN) upgraded to Overweight from Neutral at Piper Jaffray with analyst Troy Jensen saying Ciena reported another strong quarter with October beating sales consensus estimates. 3. Bristol-Myers (BMY) upgraded to Buy from Hold at Argus with analyst David Toung saying his view on the progress of the company advancing the pipeline of assets combined with Celgene has improved, particularly with two Celgene drugs - Reblozyl and Inrebic - receiving FDA approval since the merger. 4. Bluebird Bio (BLUE) upgraded to Outperform from Perform at Oppenheimer with analyst Mark Breidenbach saying that given registration-enabling data for ide-cel in hand and undeniably positive updates for lentiglobin/Zynteglo presented at the American Society of Hematology meeting, he anticipates less headwind for bluebird heading into 2020. 5. NuVasive (NUVA) upgraded to Outperform from Market Perform at SVB Leerink with analyst Richard Newitter saying he raised his 2020-2021 sales and earnings forecasts above consensus, due to more bullish top-line growth assumptions, specifically in U.S. Spinal Hardware. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Bluebird Bio upgraded following ASH updates at Oppenheimer » 07:20
12/13/19
12/13
07:20
12/13/19
07:20
BLUE

Bluebird Bio

$84.00 /

-2.97 (-3.42%)

Oppenheimer analyst Mark…

Oppenheimer analyst Mark Breidenbach upgraded bluebird bio to Outperform from Perform with a $135 price target. In a research note to investors, Breidenbach says that given registration-enabling data for ide-cel in hand and undeniably positive updates for lentiglobin/Zynteglo presented at the American Society of Hematology meeting, he anticipates less headwind for bluebird heading into 2020. The analyst expects pivotal data from KarMMa to support FDA approval of ide-cel by late 2020, and believes new data from competing products could help calibrate expectations for its commercial potential.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Bluebird Bio upgraded to Outperform from Perform at Oppenheimer » 20:08
12/12/19
12/12
20:08
12/12/19
20:08
BLUE

Bluebird Bio

$84.00 /

-2.97 (-3.41%)

Oppenheimer analyst Mark…

Oppenheimer analyst Mark Breidenbach upgraded Bluebird Bio to Outperform from Perform with a $135 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Bluebird Bio ASH updates 'not enough' to alter Piper's Neutral stance » 15:22
12/10/19
12/10
15:22
12/10/19
15:22
BLUE

Bluebird Bio

$86.00 /

+9.28 (+12.10%)

, BMY

Bristol-Myers

$62.17 /

+0.85 (+1.39%)

Piper Jaffray analyst…

Piper Jaffray analyst Tyler Van Buren said the beta thal and sickle cell updates offered by Bluebird Bio (BLUE) at the ASH medical meeting were "solid as per usual," adding that "LentiGlobin continues to look like a cure for most patients." In terms of myeloma, he believes Bluebird and partner Bristol-Myers (BMY) are "prudent" in accelerating ide-cel development. While admitting he is "tempted to get more constructive at these levels," the ASH updates were "not enough" to alter his stance and he keeps a Neutral rating on Bluebird shares, as he believes "reasonable" estimates for bb2121 are already assumed in the stock price, Van Buren tells investors.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Bluebird Bio, Bristol-Myers present update on Phase 1 study of bb21217 » 18:24
12/09/19
12/09
18:24
12/09/19
18:24
BLUE

Bluebird Bio

$76.72 /

-2.79 (-3.51%)

, BMY

Bristol-Myers

$61.32 /

+1.38 (+2.30%)

Bluebird bio (BLUE) and…

Bluebird bio (BLUE) and Bristol-Myers Squibb (BMY) announced updated safety and efficacy results from the ongoing Phase 1 study (CRB-402) of bb21217, an investigational BCMA-targeted chimeric antigen receptor T cell therapy being studied in patients with relapsed/refractory multiple myeloma. The data were presented at the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, Florida. bb21217 is an investigational BCMA-targeted CAR T cell therapy that uses the idecabtagene vicleucel CAR molecule and is cultured with the PI3 kinase inhibitor to enrich for T cells displaying a memory-like phenotype with the intention to increase the in vivo persistence of CAR T cells. "Early data from the CRB-402 study in heavily pre-treated patients (median of six prior lines) with relapsed/refractory multiple myeloma demonstrate the potential for durable responses following bb21217 CAR T cell treatment, with a median duration of response of 11.1 months at the 150 x 106 CAR+ T cell dose level," said David Davidson, M.D., chief medical officer, bluebird bio. "Consistent with the hypothesis underlying the bb21217 program that memory-like phenotype T cells may survive longer in vivo, we have observed durable CAR T cell persistence in evaluable patients with ongoing response at up to 18 months following treatment. We are continuing to recruit additional patients in the study and performing ongoing assessments of the functional persistence of bb21217, as well as its potential correlation to durability of response." "The data of CRB-402 provide additional support that targeting BCMA with a CAR T therapy could be beneficial in treating relapsed/refractory multiple myeloma, particularly for heavily pre-treated patients," said Kristen Hege, M.D., Senior Vice President, Hematology/Oncology and Cell Therapy, Early Clinical Development for Bristol-Myers Squibb. "We have observed durable responses with bb21217 in this study and look forward to further results." "One of the challenges in treating patients with relapsed/refractory multiple myeloma is that they often become resistant to currently available therapies and response durations generally shorten with each subsequent therapy," said presenting author Jesus Berdeja, M.D., Sarah Cannon Center for Blood Cancers, Nashville, Tennessee. "In this heavily-treated patient population, we are encouraged by the results with bb21217 treatment in this ongoing study."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.